Coagulation cascade factors

The coagulation cascade factors are a group of plasma proteins that work in a coordinated sequence to achieve hemostasis through the formation of a fibrin clot (Palta et al., 2014). This process involves two primary pathways—the intrinsic and extrinsic pathways—which converge on a common pathway to activate prothrombin into thrombin, the central enzyme of the cascade (Chaudhry et al., 2023). While essential for preventing blood loss after injury, dysregulation of these factors can lead to pathological thrombosis, contributing to conditions such as deep vein thrombosis, pulmonary embolism, and stroke (Gale, 2011). Pharmacological management of the cascade includes anticoagulants that inhibit specific factors like Factor Xa or Thrombin to prevent clots, as well as procoagulant therapies that replace missing factors in patients with hemophilia (NIH, 2023). Balancing the antithrombotic efficacy of these drugs against the inherent risk of major bleeding remains a primary clinical challenge in managing patients. Modern drug development focuses on highly specific inhibitors to minimize off-target effects and improve the safety profile of long-term anticoagulation.

Other names

Blood clotting factorsHemostatic factorsCoagulation factorsClotting cascade

Direct or indirect inhibition of clotting factors (e.g., Factor Xa, Thrombin), Vitamin K antagonism, or replacement of deficient factors to restore hemostasis (StatPearls, 2023; NIH, 2023).